Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDO-JAK dose reduction of JAK inhibitors in inflammatory rheumatic diseases
NL-OMON60835Phase 4Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Sep 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Proportion of patients in low disease activity at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON60835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60835.